5.65
+0.21(+3.86%)
Currency In USD
| Previous Close | 5.44 |
| Open | 5.53 |
| Day High | 5.95 |
| Day Low | 5.45 |
| 52-Week High | 12.02 |
| 52-Week Low | 1.03 |
| Volume | 1.75M |
| Average Volume | 2.75M |
| Market Cap | 612.43M |
| PE | -4.71 |
| EPS | -1.2 |
| Moving Average 50 Days | 2.92 |
| Moving Average 200 Days | 3.54 |
| Change | 0.21 |
If you invested $1000 in Tango Therapeutics, Inc. (TNGX) since IPO date, it would be worth $552.3 as of July 03, 2025 at a share price of $5.65. Whereas If you bought $1000 worth of Tango Therapeutics, Inc. (TNGX) shares 3 years ago, it would be worth $1,114.4 as of July 03, 2025 at a share price of $5.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
GlobeNewswire Inc.
Jun 27, 2025 11:00 AM GMT
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been do
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewswire Inc.
May 27, 2025 11:00 AM GMT
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annu
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
GlobeNewswire Inc.
May 21, 2025 11:00 AM GMT
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dos